- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07854249
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with impaired renal function and participants on hemodialysis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Incyte Corporation Call Center (US)
- Numéro de téléphone: 1.855.463.3463
- E-mail: medinfo@incyte.com
Sauvegarde des contacts de l'étude
- Nom: Incyte Corporation Call Center (ex-US)
- Numéro de téléphone: +800 00027423
- E-mail: eumedinfo@incyte.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Ability to comprehend and willingness to sign a written ICF for the study.
-
Aged 18 to 85 years, inclusive, at the time of signing the ICF.
-
Severe renal impairment or ESRD based on CKD-EPI (National Kidney Foundation).
• Participants with impaired renal function should have stable renal function (ie, those with acute changes in renal function should not be enrolled in the study).
-
Medical findings consistent with the degree of renal dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory determinations at screening or check-in (as applicable). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible.
-
BMI of 18.0 to 43.0 kg/m2 (inclusive) at screening.
-
Ability to swallow and retain oral tablets.
-
Willingness to avoid pregnancy, breastfeeding, or fathering children.
Exclusion Criteria:
-
History of uncontrolled or unstable cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, or neurological disease within 6 months before screening.
- History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including but not limited to the following:
- Recent myocardial infarction (within 6 months before check-in).
- New York Heart Association Class III or IV congestive heart failure.
- Unstable angina (within 6 months before check-in).
- Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker).
- Uncontrolled hypertension.
-
Participants who have a current, functioning organ transplant or are on the national transplant list and expected to receive a transplant within 3 months.
-
History of an autoimmune disease diagnosis (eg, myasthenia gravis).
-
History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg at screening, confirmed by repeat testing).
-
Participants who have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
-
Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).
-
History of malignancy within 5 years before screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
-
Current or recent (within 3 months before screening) clinically significant GI disease or surgery (including cholecystectomy [< 2 months]; excluding appendectomy and hernia repair) that could affect the absorption of study drug.
-
Confirmed resting pulse rate (up to 2 consecutive measurements) < 40 bpm or > 100 bpm at screening.
-
Participants with laboratory values outside the accepted range for participants with severe renal impairment or ESRD at screening.
-
Any major surgery within 4 weeks before screening. Note: This does not include procedure for HD.
-
Blood transfusion within 4 weeks before check-in (Day -1).
-
Chronic or current active infectious disease (including latent tuberculosis) requiring systemic antibiotic, antifungal, or antiviral treatment.
-
Positive test result for HBV, HCV, or HIV. Upon testing, HBV DNA and HCV RNA must be undetectable.
- Note 1: Participants with no prior history of HBV infection who have been vaccinated against HBV and who have a positive HBsAg antibody test as the only evidence of prior exposure may participate in the study.
- Note 2: Participants who have cleared a prior HBV infection (defined as HbsAg negative, HBsAb positive, or HBcAb positive) may be included at the discretion of the investigator.
-
Receipt of any vaccine including but not limited to live (including attenuated), influenza, and SARS-CoV-2 vaccines within 3 months before the first dose of study drug.
-
Medical or self-reported history of alcoholism within 3 years before screening.
-
History of significant alcohol use, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females, within 3 months before screening.
-
Treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another investigational medication or current enrollment in another investigational drug study.
-
Treatment within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database Program for prohibited drugs).
-
Active infection requiring systemic therapy.
-
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
-
Known hypersensitivity or severe reaction to INCB161734, any excipients of INCB161734, or any KRAS inhibitors (refer to the IB).
-
Inability to undergo venipuncture or tolerate venous access, or inadequate veins for repeat venipuncture or venous access as determined by the investigator.
-
Tobacco or nicotine-containing product use of > 10 cigarettes per day within 1 month before screening.
-
Use of prescription drugs (including hormonal contraceptives) within 14 days before study drug administration or nonprescription medications/products (including megadose vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations as well as pre/probiotics) within 7 days of study drug administration
- Note 1: Occasional acetaminophen, standard-dose ibuprofen, and standard-dose vitamins are permitted.
- Note 2: Established therapy for renal disease, or the treatment of associated disorders, that has been stable for at least 7 days prior to study drug administration, is allowed if approved by the medical monitor and investigator.
-
Participants who are pregnant or lactating.
-
Excessive exercise (eg, Ironman, bi/triathlon) within 3 months before screening.
-
Participants who had a change in disease status within 30 days before screening, as documented by the participant's medical history, that is deemed clinically significant by the investigator.
-
Participants who have a history of paracentesis within 3 months prior to check-in.
-
Participants who required new medication or an increase in dose for renal disease within 3 months prior to check-in.
-
Participants who have a history of unstable diabetes mellitus (as evidenced by hemoglobin A1c ≥ 10.0%). Medications for treatment of diabetes mellitus must be reviewed and approved by the investigator and medical monitor.
-
Esophageal banding within 3 months prior to check-in or required any other treatment for GI bleeding within 6 months prior to check-in.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Group 1: Severe renal impairment
Participants with severe renal impairment will be enrolled in Group 1. |
single dose administered orally |
|
Expérimental: Group 2: End-stage renal disease (ESRD)
Participants with end-stage renal disease will be enrolled in Group 2. |
single dose administered orally |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
PK for plasma INCB161734: Cmax
Délai: Up to approximately 3.5 months
|
Defined as the maximum plasma concentration. |
Up to approximately 3.5 months
|
|
PK for plasma INCB161734: AUClast
Délai: Up to approximately 3.5 months
|
Defined as the area under the concentration-time curve from time zero to time of the last quantifiable concentration. |
Up to approximately 3.5 months
|
|
PK for plasma INCB161734: AUCinf
Délai: Up to approximately 3.5 months
|
Defined as the area under concentration-time curve from time zero extrapolated to infinity. |
Up to approximately 3.5 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Treatment-Emergent Adverse Events (TEAEs)
Délai: Up to approximately 3.5 months and 30 days
|
Adverse events reported for the first time or worsening of a pre-existing event, occurring after first dose of study drug. |
Up to approximately 3.5 months and 30 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Incyte Medical Monitor, Incyte Corporation
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Processus pathologiques
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladie chronique
- Attributs de la maladie
- Insuffisance rénale chronique
- Conditions pathologiques, signes et symptômes
- Insuffisance rénale
- Maladies rénales
- Insuffisance rénale chronique
Autres numéros d'identification d'étude
- INCB161734-106
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .